Alignment Healthcare (ALHC) CEO sells shares to cover RSU tax withholding

Rhea-AI Filing Summary

Alignment Healthcare, Inc. Chief Executive Officer John E. Kao reported selling a total of 48,899 shares of common stock in open-market transactions on March 12, 2026. The shares were sold at weighted-average prices of $17.476 and $16.9919 per share.

According to the disclosure, these sales were required to cover tax withholding obligations triggered by the vesting of restricted stock units and did not represent discretionary trading decisions by Mr. Kao. After the transactions, he held 1,519,480 shares directly.

The filing also reports 2,472,641 shares of common stock held indirectly through the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee, providing additional indirect economic exposure to Alignment Healthcare stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		S		45,938(1)	D	$17.476(2)	1,522,441	D
Common Stock	03/12/2026		S		2,961(1)	D	$16.9919(3)	1,519,480	D
Common Stock								2,472,641	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This transaction does not represent a discretionary trade by the reporting person.

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $17.035 to $18.03. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.92 to $17.03. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

4. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Alignment Healthcare (ALHC) disclose in this Form 4 filing?

Alignment Healthcare reported that CEO John E. Kao sold 48,899 shares of common stock on March 12, 2026. The filing explains these sales covered tax withholding from restricted stock unit vesting and were not discretionary trades, while also updating his direct and indirect share holdings.

How many Alignment Healthcare (ALHC) shares did the CEO sell and at what prices?

CEO John E. Kao sold 45,938 shares at a weighted-average price of $17.476 and 2,961 shares at $16.9919. The transactions occurred on March 12, 2026, in multiple trades within disclosed intraday price ranges for each block of shares.

Why did Alignment Healthcare (ALHC) CEO John Kao sell these shares?

The filing states the sold shares were required to cover tax withholding obligations arising from the vesting of restricted stock units. It explicitly notes the transactions do not represent discretionary trades by Mr. Kao, framing them as a mechanical consequence of equity compensation vesting.

How many Alignment Healthcare (ALHC) shares does the CEO still hold after the sale?

After the reported sales, CEO John E. Kao directly owned 1,519,480 shares of Alignment Healthcare common stock. In addition, the filing lists 2,472,641 shares held indirectly through the JEK Trust, dated February 8, 2021, where he serves as trustee.

What is the JEK Trust mentioned in the Alignment Healthcare (ALHC) Form 4?

The JEK Trust, dated February 8, 2021, holds 2,472,641 Alignment Healthcare shares reported as indirectly owned. The filing explains these securities are held by the trust, with Mr. Kao serving as trustee, providing him indirect beneficial exposure to the company’s common stock.

Were the Alignment Healthcare (ALHC) CEO share sales part of a trading strategy?

The disclosure states the transactions were to satisfy tax withholding from restricted stock unit vesting and explicitly notes they were not discretionary trades. This characterizes the sales as administrative, compensation-related events rather than deliberate timing decisions about Alignment Healthcare’s stock.